论文部分内容阅读
目的:评价猕猴桃根多糖脂质体口服液的抗急性肝损伤作用。方法:采用CCl4所致小鼠急性肝损伤模型,以联苯双酯作为阳性对照药,通过测定肝损伤小鼠的血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、测定肝损伤小鼠肝脏中的超氧化物歧化酶(SOD)、丙二醛(MDA)等指标,观察肝组织病理改变,研究APPS多相脂质体口服液的抗急性肝损伤药效作用;结果:与模型组比较,APPS多相脂质体口服液高剂量(200 mg·kg-1)、中剂量(100 mg·kg-1)可显著降低血清中ALT、AST含量(P<0.05),有效提高肝组织SOD活力、降低MDA含量(P<0.05),与联苯双酯的药效作用无统计学差异。结论:APPS多相脂质体口服液对CCl4所致小鼠急性肝损伤有显著的保护作用。
Objective: To evaluate the anti-acute liver injury effect of kiwifruit lipopolysaccharide oral solution. Methods: Acute liver injury induced by CCl4 was induced in mice and bifendate was used as a positive control. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (SOD), malondialdehyde (MDA) were measured to observe the pathological changes of liver tissue and study the anti-acute liver injury efficacy of APPS multi-phase liposome oral solution.Results: Compared with the model group , High dose (200 mg · kg -1) and medium dose (100 mg · kg -1) of APPS multiphase liposomes could significantly reduce the content of ALT and AST in serum (P <0.05) Vitality, reduce MDA content (P <0.05), and the efficacy of bifendate no significant difference. Conclusion: APPS multiphase liposome has a significant protective effect on acute liver injury induced by CCl4 in mice.